TipRanks
Prime Medicine, Inc. (PRME)
NASDAQ:PRME
US Market
PRME
Prime Medicine, Inc.
RESEARCH TOOLSreports
Want to see PRME full AI Analyst Report?

Prime Medicine, Inc. (PRME) Stock Forecast & Price Target

927 Followers
See the Price Targets and Ratings of:

PRME Analyst Ratings

Strong Buy
8Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Prime
Medicine, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PRME Stock 12 Month Forecast

Average Price Target

$7.67
▲(114.15% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Prime Medicine, Inc. in the last 3 months. The average price target is $7.67 with a high forecast of $11.00 and a low forecast of $5.00. The average price target represents a 114.15% change from the last price of $3.58.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","12":"$12","3.75":"$3.75","6.5":"$6.5","9.25":"$9.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.666666666666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.75,6.5,9.25,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.99,3.6061538461538465,4.222307692307693,4.838461538461539,5.454615384615385,6.070769230769232,6.686923076923077,7.303076923076923,7.9192307692307695,8.535384615384615,9.151538461538461,9.767692307692307,10.383846153846154,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.99,3.34974358974359,3.70948717948718,4.069230769230769,4.42897435897436,4.788717948717949,5.148461538461539,5.5082051282051285,5.867948717948718,6.227692307692308,6.587435897435898,6.947179487179488,7.306923076923077,{"y":7.666666666666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.99,3.144615384615385,3.2992307692307694,3.453846153846154,3.6084615384615386,3.763076923076923,3.917692307692308,4.072307692307692,4.226923076923077,4.381538461538462,4.536153846153846,4.690769230769231,4.845384615384615,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.59,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.66,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.39,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.41,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.89,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.99,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$11.00Average Price Target$7.67Lowest Price Target$5.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on PRME
Cory Jubinville, PhD
LifeSci Capital
LifeSci Capital
$6
Buy
67.60%
Upside
Reiterated
10/05/26
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX) and Prime Medicine, Inc. (NASDAQ: PRME)
H.C. Wainwright Analyst forecast on PRME
Arthur He CFA
H.C. Wainwright
H.C. Wainwright
$8
Buy
123.46%
Upside
Reiterated
10/01/26
Prime Medicine, Inc. (PRME) Gets a Buy from H.C. Wainwright
Oppenheimer Analyst forecast on PRME
Kostas Biliouris
Oppenheimer
Oppenheimer
$11
Buy
207.26%
Upside
Reiterated
09/25/26
Oppenheimer Remains a Buy on Prime Medicine, Inc. (PRME)
BMO Capital Analyst forecast on PRME
David Lebowitz
BMO Capital
BMO Capital
$9
Buy
151.40%
Upside
Reiterated
09/24/26
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (NASDAQ: PRME) and Merck & Company (NYSE: MRK)
TD Cowen Analyst forecast on PRME
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
09/24/26
Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Edgewise Therapeutics (EWTX)
Chardan Capital Analyst forecast on PRME
Keay Nakae
Chardan Capital
Chardan Capital
$7
Buy
95.53%
Upside
Reiterated
09/24/26
Chardan Capital Sticks to Their Buy Rating for Prime Medicine, Inc. (PRME)
Morgan Stanley Analyst forecast on PRME
Terence Flynn
Morgan Stanley
Morgan Stanley
―
Hold
―
Assigned
08/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (NASDAQ: LKFT), Prime Medicine, Inc. (NASDAQ: PRME) and Electrocore (NASDAQ: ECOR)
JonesTrading Analyst forecast on PRME
Boris Peaker
JonesTrading
JonesTrading
$5
Buy
39.66%
Upside
Reiterated
08/06/26
Prime Medicine: Buy Rating Reiterated with Unchanged $5 Price Target on Emerging Clinical Catalysts in Wilson’s Disease
Wedbush Analyst forecast on PRME
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$8
Buy
123.46%
Upside
Reiterated
06/22/26
Wedbush Keeps Their Buy Rating on Prime Medicine, Inc. (PRME)
J.P. Morgan Analyst forecast on PRME
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Hold
―
Reiterated
11/18/25
Prime Medicine transferred with Neutral rating at JPMorganPrime Medicine transferred with Neutral rating at JPMorgan
Citi Analyst forecast on PRME
Samantha Semenkow
Citi
Citi
$5→$4.25
Hold
18.72%
Upside
Reiterated
11/11/25
Prime Medicine price target lowered to $4.25 from $5 at CitiPrime Medicine price target lowered to $4.25 from $5 at Citi
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on PRME
Cory Jubinville, PhD
LifeSci Capital
LifeSci Capital
$6
Buy
67.60%
Upside
Reiterated
10/05/26
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (NASDAQ: PRAX) and Prime Medicine, Inc. (NASDAQ: PRME)
H.C. Wainwright Analyst forecast on PRME
Arthur He CFA
H.C. Wainwright
H.C. Wainwright
$8
Buy
123.46%
Upside
Reiterated
10/01/26
Prime Medicine, Inc. (PRME) Gets a Buy from H.C. Wainwright
Oppenheimer Analyst forecast on PRME
Kostas Biliouris
Oppenheimer
Oppenheimer
$11
Buy
207.26%
Upside
Reiterated
09/25/26
Oppenheimer Remains a Buy on Prime Medicine, Inc. (PRME)
BMO Capital Analyst forecast on PRME
David Lebowitz
BMO Capital
BMO Capital
$9
Buy
151.40%
Upside
Reiterated
09/24/26
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (NASDAQ: PRME) and Merck & Company (NYSE: MRK)
TD Cowen Analyst forecast on PRME
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
09/24/26
Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Edgewise Therapeutics (EWTX)
Chardan Capital Analyst forecast on PRME
Keay Nakae
Chardan Capital
Chardan Capital
$7
Buy
95.53%
Upside
Reiterated
09/24/26
Chardan Capital Sticks to Their Buy Rating for Prime Medicine, Inc. (PRME)
Morgan Stanley Analyst forecast on PRME
Terence Flynn
Morgan Stanley
Morgan Stanley
―
Hold
―
Assigned
08/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (NASDAQ: LKFT), Prime Medicine, Inc. (NASDAQ: PRME) and Electrocore (NASDAQ: ECOR)
JonesTrading Analyst forecast on PRME
Boris Peaker
JonesTrading
JonesTrading
$5
Buy
39.66%
Upside
Reiterated
08/06/26
Prime Medicine: Buy Rating Reiterated with Unchanged $5 Price Target on Emerging Clinical Catalysts in Wilson’s Disease
Wedbush Analyst forecast on PRME
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$8
Buy
123.46%
Upside
Reiterated
06/22/26
Wedbush Keeps Their Buy Rating on Prime Medicine, Inc. (PRME)
J.P. Morgan Analyst forecast on PRME
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Hold
―
Reiterated
11/18/25
Prime Medicine transferred with Neutral rating at JPMorganPrime Medicine transferred with Neutral rating at JPMorgan
Citi Analyst forecast on PRME
Samantha Semenkow
Citi
Citi
$5→$4.25
Hold
18.72%
Upside
Reiterated
11/11/25
Prime Medicine price target lowered to $4.25 from $5 at CitiPrime Medicine price target lowered to $4.25 from $5 at Citi
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ZVRAZevra Therapeutics
DFTXDefinium Therapeutics
HITIHigh Tide
DNLIDenali Therapeutics
MDWDMediwound
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Prime Medicine, Inc.

3 Months
Kostas BiliourisOppenheimer
Success Rate
4/15 ratings generated profit
27%
Average Return
-11.57%
Copying Kostas Biliouris's trades and holding each position for 3 Months would result in 26.67% of your transactions generating a profit, with an average return of -11.57% per trade.
1 Year
Kostas BiliourisOppenheimer
Success Rate
6/15 ratings generated profit
40%
Average Return
-9.65%
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -9.65% per trade.
2 Years
Kostas BiliourisOppenheimer
Success Rate
4/15 ratings generated profit
27%
Average Return
-18.35%
Copying Kostas Biliouris's trades and holding each position for 2 Years would result in 26.67% of your transactions generating a profit, with an average return of -18.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRME Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
10
13
14
14
12
Buy
2
2
1
2
1
Hold
3
4
3
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
19
18
18
14
In the current month, PRME has received 13 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. PRME average Analyst price target in the past 3 months is 7.67.
Each month's total comprises the sum of three months' worth of ratings.

PRME Financial Forecast

PRME Earnings Forecast

Next quarter’s earnings estimate for PRME is -$0.24 with a range of -$0.28 to -$0.19. The previous quarter’s EPS was -$0.24. PRME beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year PRME has Performed in-line its overall industry.
Next quarter’s earnings estimate for PRME is -$0.24 with a range of -$0.28 to -$0.19. The previous quarter’s EPS was -$0.24. PRME beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year PRME has Performed in-line its overall industry.

PRME Sales Forecast

Next quarter’s sales forecast for PRME is $1.32M with a range of $0.00 to $3.00M. The previous quarter’s sales results were $1.15M. PRME beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year PRME has Performed in-line its overall industry.
Next quarter’s sales forecast for PRME is $1.32M with a range of $0.00 to $3.00M. The previous quarter’s sales results were $1.15M. PRME beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year PRME has Performed in-line its overall industry.

PRME Stock Forecast FAQ

What is PRME’s average 12-month price target, according to analysts?
Based on analyst ratings, Prime Medicine, Inc.’s 12-month average price target is 7.67.
    What is PRME’s upside potential, based on the analysts’ average price target?
    Prime Medicine, Inc. has 114.15% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PRME a Buy, Sell or Hold?
          Prime Medicine, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Prime Medicine, Inc.’s price target?
            The average price target for Prime Medicine, Inc. is 7.67. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $11.00 ,the lowest forecast is $5.00. The average price target represents 114.15% Increase from the current price of $3.58.
              What do analysts say about Prime Medicine, Inc.?
              Prime Medicine, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of PRME?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.